Copyright 2024 The Science Publishers
All Rights Reserved for Website Design.
.png){kind=small}
ISSN 2410-955X - An International Biannual Journal
Computational drug designing: A new paradigm for the treatment of Parkinson's disease
Fatima Noor*, Mavra Khalid, Amna Saeed
Department of Bioinformatics and Biotechnology, Government College University Faisalabad, Pakistan
Abstract
Parkinson's disease is the second age related neurodegenerative disorder, affects almost 10 million people worldwide. Sporadic cases of PD resulted from aging and environmental factors while familial cases resulted from mutations in LRRK2, SNCA, PRKN, GBA, UCHL1, DJ-1, and PINK1. However, some genes mutations are not inherited (sporadic). Computational approaches played a major role in the development of drug used in clinical practice. These computational methods have evolved with the experimental methods that underpin the development of novel compounds against disease. In this review article we elaborate mechanisms of gene variants involves in Parkinson's disease, to epitomize computationally derived inhibitors against these variants, utilizing in silico approaches to find the molecules and explain the effect of particular molecule binds with target molecules.
A R T I C L E I N F O
Received
March 01, 2020
Revised
April 29, 2020
Accepted
June 01, 2020
*Corresponding Author
Fatima Noor
E-mail
fatimanoor1122@yahoo.com
Keywords
Parkinson's disease
Computational drug designing
Mutations
Inhibitors
Review article
2020 | Volume 6 | Issue 2: Special issue articles: Computational drug designing and molecular docking analyses